Understanding how Klebsiella pneumoniae becomes resistant to polymyxin antibiotics
Elucidating the genotypic determinants and phenotypic effects of polymyxin resistance in Klebsiella pneumoniae utilizing CRISPR-Cas9
This study is looking at how certain genetic changes in the bacteria Klebsiella pneumoniae make it resistant to important antibiotics, which could help doctors find better ways to treat serious infections for patients like you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10890808 on NIH RePORTER |
What this research studies
This research investigates the genetic factors that lead to resistance in Klebsiella pneumoniae against polymyxin antibiotics, which are critical for treating severe infections. By utilizing advanced CRISPR-Cas9 technology, the study aims to identify specific mutations in the bacteria that contribute to this resistance and how these mutations affect the bacteria's ability to survive and cause disease. The research involves a combination of genetic analysis and laboratory experiments to validate the findings and understand the implications for treatment options. Patients may benefit from improved strategies to combat antibiotic-resistant infections as a result of this work.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from infections caused by Klebsiella pneumoniae, particularly those with antibiotic-resistant strains.
Not a fit: Patients with infections caused by other types of bacteria that do not involve Klebsiella pneumoniae may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new insights and strategies for treating infections caused by antibiotic-resistant Klebsiella pneumoniae.
How similar studies have performed: Previous research has shown success in using CRISPR technology to study antibiotic resistance, indicating that this approach has potential for meaningful discoveries.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Mcconville, Thomas Howe — Columbia University Health Sciences
- Study coordinator: Mcconville, Thomas Howe
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.